Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst expectations, driven by strong demand for its cystic ...

Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up from $408. Published first on TheFly – the ultimate source for real-time, market-moving ...

Vertex is faced with an access challenge as it is charging $15.50 for a 50 mg dose of Journavx, which works out to $420 for a two-week course. Generic opioids, meanwhile, go for roughly $0.50 a pill.

--(BUSINESS WIRE)--NEXT Energy Technologies, a pioneer in organic photovoltaic (OPV) technology, has completed an upgrade of its pilot production line to produce 40” x 60” laminated ...

NEXT’s proprietary transparent organic photovoltaic (OPV) coating can transform commercial windows into clean energy-generating facades, making buildings more sustainable and resilient and ...

NEXT Energy Technologies, a pioneer in organic photovoltaic (OPV) technology, has completed an upgrade of its pilot production line to produce 40” x 60” laminated transparent power-generating ...

Vertex Pharmaceuticals beat expectations for revenue but missed on earnings. The company has two recent FDA approvals and several treatments in late-stage trials. The core CF treatments make up ...

Sign up for the Marketplace newsletter to get the day’s biggest business stories, our economic analysis, and explainers to help you live smarter, straight to your ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.